Since Septerna’s inception in 2019, the company had raised $224.2 million prior to the IPO, most recently a $150 million Series B round last year led by RA Capital Management.That firm holds a 7 ...

--Septerna, Inc., a biotechnology company pioneering a new era of G protein-coupled receptor drug discovery, today highlighted key business updates and upcoming milestones and reported financial ...

Septerna, Inc. ( (SEPN) ) has released its Q3 earnings. Here is a breakdown of the information Septerna, Inc. presented to its investors. Septerna, Inc. is a clinical-stage biotechnology company ...

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases. Novo will cover all research-and-development costs ...

Septerna, Inc. is a clinical-stage biotechnology company pioneering a new era of GPCR oral small molecule drug discovery powered by its proprietary Native Complex Platform™.

A couple of analysts initiated coverage on Septerna, Inc. (NASDAQ:SEPN), which debuted on NASDAQ last month. Cantor analyst Josh Schimmer initiated coverage at an Overweight rating with a price ...

TD Cowen initiated coverage of Septerna (SEPN) with a Buy rating and no price target The company is applying its Native Complex platform to build a pipeline of oral small molecule G protein ...

Septerna is allocating $54 million of the IPO proceeds to continue SEP-786’s clinical journey into a phase 2 study. A further $24 million is earmarked for taking its chronic spontaneous ...

Septerna, a biotechnology company focused on developing new small-molecule drugs for G-protein-coupled receptors (GPCRs), has sold a GPCR program to Vertex Pharmaceuticals for $47.5 million.

Septerna is also eligible to receive tiered royalties on global net sales of marketed products. Novo Nordisk will cover all R&D expenses for partnered programs under the collaboration.

SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. , a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted ...